Cylco Ltd

Cylco Ltd is a small, active company based in Oldham, UK, founded three years ago. With £58,391 in assets and a real address, it’s a solo-founded operation managed by one director and owner. The company operates in the retail sale via mail order houses or via internet industries.

The company’s website showcases a focus on developing life-changing medicines for patients and families living with challenging diseases. It highlights two primary areas of research: Niemann-Pick Disease Type C and Alzheimer's Disease, with a pipeline of clinical trials underway. The site features dedicated sections for patients and families, scientific publications, and investor relations, projecting an image of a research-driven pharmaceutical company. It’s clear they’re not just selling products; they’re building a brand around scientific innovation and patient care.

Financially, Cylco Ltd presents a mixed picture. Cash reserves have surged an impressive 44,000%, reaching £44,000—a significant turnaround. However, net losses remain, and trade debtors have increased, suggesting potential issues with customer payments. Creditors have also risen, indicating increased borrowing. Despite the small size (meeting two of three conditions for a small company), the increase in cash is a positive sign. The lack of employees (zero reported) points to a lean operation, likely relying on external contractors. The accounts are unaudited, as is common for small companies, and no auditor is mentioned.

Overall, Cylco Ltd seems to be navigating early-stage growth challenges. The surge in cash is encouraging, but the company needs to manage its debts and ensure timely customer payments to sustain its momentum. It’s a small company with big ambitions, and its success hinges on its ability to translate scientific research into marketable therapies.

Registered in England/Wales under the registration number 13909879, with a registered address at OL8 1HQ, England, Oldham, Greater Manchester, Guardian House, 11 Primrose Bank.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.